To assess the efficacy of recombinant human stem cell factor (rHuSCF), 48 patients who had failed to mobilize 42.0 Â 10 6 CD34 þ cells/kg with granulocyte colonystimulating factor (G-CSF) (10 lg/kg twice daily) with, or without, concomitant chemotherapy (G-CSF-based regimen), were remobilized with the addition of rHuSCF (20 lg/kg/day). In all, 18/48 (38%) achieved a total of 42.0 Â 10 6 CD34 þ cells/kg with the second rHuSCFbased mobilisation alone and 29/48 (60%) achieved a cumulative total of 42.0 Â 10 6 CD34 þ cells/kg following remobilization. Inclusion of chemotherapy in the mobilization regimen resulted in a higher yield of CD34 þ cells/ kg for both the initial G-CSF-based and subsequent rHuSCF-based regimens (0.90 vs 0.54, Po0.01 and 2.36 vs 1.34, Po0.01, respectively). The total peripheral blood stem cells PBSC collected from the G-CSF-based regimen, performance status, baseline platelet count and albumin were significantly associated with successful remobilization. Patients with multiple myeloma were also more likely to successfully remobilize. There was no threshold of total collected from the failed G-CSF-based regimen below which successful remobilization with the rHuSCF-based regimen was not possible. We therefore propose a predictive model [PBSC expected ¼ 0.6 þ (G-CSF-based total collection) þ 2 (rHuSCF-based day 1 collection)] to calculate the cumulative total of PBSC expected following a maximum of five leukaphereses. This algorithm may permit the early identification of patients who are unlikely to achieve sufficient PBSC for transplantation and allow physicians to direct the resources involved in PBSC collection in a more appropriate and economical manner.
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Autologous peripheral blood stem cell transplantation offers the best chance of prolonged disease-free survival for patients with certain haematological malignancies. 1, 2 In heavily pretreated patients, collecting adequate peripheral blood stem cells (PBSC) is often the limiting step to this form of therapy. 3 The ideal mobilization regimen for PBSC is yet to be clearly defined. Various parameters including age, prior chemotherapy and/or radiotherapy and bone marrow involvement with disease have been reported to affect the yield of stem cells. [3] [4] [5] [6] [7] [8] Published reports suggest that as many as 30% of heavily pretreated patients who would benefit from an autologous PBSC transplant fail to mobilize enough progenitors for this procedure. 3, 9 The transplantation of patients with less than 2 Â 10 6 CD34 þ cells/kg is associated with delayed engraftment of both neutrophils and platelets and/or engraftment failure in up to 20% of recipients. 3, 6, 10 While CD34 þ cell doses of X5 Â 10 6 /kg have the most optimum transplantation kinetics, these targets are seldom reached by most patients, especially those who are heavily pretreated. 11 Many investigators would agree that X2 Â 10 6 CD34 þ cells/kg is sufficient to achieve rapid and durable haematopoietic reconstitution. 3, 12 Recombinant human stem cell factor (rHuSCF) is a cytokine that stimulates the proliferation of lineagecommitted and nonlineage committed haematopoietic progenitor cells. 13 In vitro evidence suggests synergy between rHuSCF and other cytokines with haematopoietic proliferative potential, including granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO) and interleukin 3 and 6.
14, 15 Recent reports have focused on the in vivo cooperation between rHuSCF and G-CSF in allowing successful mobilization of PBSC for use in autologous PBSC transplants. 16, 17 The combination of rHuSCF and G-CSF with or without concomitant chemotherapy is a potent stimulus for the mobilization of PBSC. This regimen is especially effective in patients who have been heavily pretreated and failed prior attempts at stem cell mobilization.
We describe here our experience in 48 patients with the use of rHuSCF in combination with G-CSF or G-CSF/ chemotherapy for the mobilization of PBSC in patients who had previously failed to mobilize X2 Â 10 6 CD34 þ cells/kg using G-CSF alone or G-CSF/chemotherapy.
Patients and methods

Patients and study design
Between January 1998 and August 2004, patients at our institution who had failed to collect sufficient PBSC for a future autologous PBSC transplant using a G-CSF-based regimen (G-CSF plus-or-minus chemotherapy) were offered the opportunity of a subsequent attempt incorporating rHuSCF into the regimen. The rHuSCF-based mobilization (rHuSCF and G-CSF plus-or-minus chemotherapy) commenced following a minimum of 3 weeks from the original failed attempt. Patients in this study were at least 18 years of age. Only patients with a haematological malignancy suitable for treatment with high-dose chemotherapy with stem cell support were included in the study. Every patient included in this study had attempted and failed to mobilize X2.0 Â 10 6 CD34 þ cells/kg with the aid of a G-CSF-based regimen as their initial mobilization schedule. The treating physician determined the choice of whether cytokine therapy alone or cytokine-plus-chemotherapy was used for the initial G-CSF-based or subsequent rHuSCF-based mobilization attempts. There were no exclusions based on baseline neutrophil counts or the number of PBSC collected with the initial G-CSF-based regimen. We compared each patient's yield of PBSC with a G-CSF-based regimen to his/ her yield with the subsequent rHuSCF-based regimen, thus providing an internal historical control. The study was granted ethics approval at our institution.
Safety with rHuSCF injections
The drugs used for mobilization in this study were rHuSCF (ancestim; Stemgen s , Amgen Inc., Thousand Oaks, CA, USA) and G-CSF (filgrastim; Neupogen s , Amgen Inc., Thousand Oaks, CA, USA). Prior to the commencement of rHuSCF, each patient was given a patient education sheet on the potential adverse effects of the cytokine. In addition to this, the treating physician individually counselled the patients. Every patient was pre-medicated daily until the completion of the rHuSCF/G-CSF injections. The premedication schedule consisted of ranitidine 150 mg orally every 12 h, salbutamol 2 puffs from a metered dose inhaler 30 min prior to rHuSCF injections and cetrizine 10 mg orally daily. Patients were excluded from receiving rHuSCF if there was a strong history of asthma requiring hospital admission, angioedema, anaphylaxis or anaphylactoid reactions to medications presenting as generalized urticaria, laryngeal edema or severe bronchospasm.
PBSC mobilization
Patients included in the study received 10 mg/kg of G-CSF twice daily as part of their initial G-CSF-based regimen.
rHuSCF at a dose of 20 mg/kg/day was added to this for their subsequent rHuSCF-based regimen. rHuSCF and G-CSF were commenced concurrently. For patients receiving chemotherapy as part of their mobilization, the cytokines were commenced between day 10 and day 20 after the completion of chemotherapy. These cytokines were administered at the same daily dose until completion of leukaphereses. Leukapheresis was commenced on day 5 of cytokine therapy. A maximum of five leukaphereses were scheduled. Leukapheresis was ceased prior to this if X3.0 Â 10 6 CD34 þ cells/kg were collected in total, if two successive collections of p0.2 Â 10 6 CD34 þ cells/kg were achieved or if the daily total of PBSC harvested was substantially less than the previous day. Seven patients included in this study were part of a multicentre trial and the mobilization schedule used in these patients has been previously described. 16 These seven patients received 5 mg/ kg of G-CSF twice daily as part of both the G-CSF-based and rHuSCF-based regimens; five of these patients were successfully collected.
We processed a standard of 7 l of blood per leukapheresis as this had previously been shown to be as efficient as a larger volume leukapheresis. 18 Between January 1998 and December 2002 patients were leukapheresed exclusively on a Fenwal CS3000 plus (Baxter, Deerfield, IL, USA). However, between December 2002 and August 2004 leukapheresis was performed either on the Fenwal CS 3000 plus or the Cobe Spectra (Gambro BCT, Lakewood, CO, USA). While there has been some conflicting evidence regarding the collection efficiency of the two cell separators, [19] [20] [21] neither has been shown to be unequivocally superior to the other. The leukapheresis procedure on the two different cell separators has been previously described.
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Data collection and statistical methods
Demographic and baseline characteristics were collected on all the patients involved (Table 1) . Patients were categorized into two groups based on the amount of prior chemotherapy and/or radiotherapy they had received. Patients were deemed to have been heavily pre-treated if they had received 42 cycles of mechlorethamine, procarbazine HCI, a nitrosourea such as BCNU, melphalan, X7 g of cytosine arabinoside, X10 cycles of chemotherapy, or radiotherapy to the mediastinum, abdomen or pelvis excluding spot radiation. All other patients were classified as minimally pre-treated. The number of leukaphereses performed on each patient, any adverse reaction whilst being leukapheresed and the number of CD34 þ cells/kg harvested each session were also recorded.
All analyses were performed using SAS version 8.2. (SAS Institute Inc., Cary, NC, USA). A cumulative total of 2.0 Â 10 6 /kg of CD34 þ cells (G-CSF-based total plus rHuSCF-based total) was taken as the most clinically relevant end point. Univariate analysis was performed on categorical data using X 2 for equal proportion, whereas continuous data were assessed using Student's t-tests and further validated using Wilcoxon rank sum tests. Multivariate analysis was performed using multiple linear regression and multiple logistic regression. Multivariate models were constructed using a stepwise selection technique considering all possible predictors and validated using a backward elimination technique. Each final model was further assessed for clinical and biological plausibility. A two-sided P-value of 0.05 was considered to be statistically significant.
Results
Overall, 52 patients at our institute received rHuSCF prior to PBSC harvest. However, four of these patients had not previously failed an attempt to collect X2.0 Â 10 6 CD34 þ cells/kg with a G-CSF-based regimen. These patients were excluded from the current analysis. The median age of the patients prior to either the G-CSF-based or rHuSCF-based PBSC mobilization was 55 years. The majority of patients, 41/48 (85%) was heavily pre-treated. At the managing physician's discretion, five patients with an ECOG status of 3 were included in this cohort; none of them collected sufficient PBSC to proceed to transplantation.
On the G-CSF-based regimen, 22 patients received chemotherapy as part of their mobilization, 10 of these patients did not subsequently receive chemotherapy as part of their rHuSCF-based regimen. The reasons for exclusion of chemotherapy in these 10 patients were either an adverse reaction (four patients), or because they had completed a pre-determined schedule of salvage chemotherapy (six patients). None of the patients who were initially mobilized with G-CSF alone were remobilized with chemotherapy as part of the rHuSCF-based regimen. The PBSC yield in patients mobilized with chemotherapy vs no chemotherapy as part of both the G-CSF-based and rHuSCF-based mobilizations regimens is summarized in Table 2 . This favours a higher yield of PBSC with the use of chemotherapy as part of the mobilization schedule in this patient cohort.
All patients completed the scheduled duration of cytokine therapy with rHuSCF and G-CSF. The incidence of localized skin reactions and pruritus to the rHuSCF injection was 42%. There were no systemic reactions recorded and there were no withdrawals from the scheduled therapy as a result of an adverse reaction to the medication.
Overall, 18/48 (38%) of the patients who had failed a previous collection with a G-CSF-based regimen were successful in attaining 42.0 Â 10 6 CD34 þ cells/kg with their rHuSCF-based regimen alone. When the yield from the G-CSF-based regimen was added to the rHuSCFbased regimen, 29/48 (60%) of patients achieved a cumulative total of 42.0 Â 10 6 CD34 þ cells/kg ( Figure 1 ). The remobilization success by disease category is summarized in Table 3 .
The mean number of leukaphereses with the G-CSFbased regimen vs the rHuSCF-based regimen was not significantly different (2.4 vs 2.7; P ¼ 0.11). As part of the rHuSCF-based regimen, one patient underwent six leukaphereses. The managing physician made the decision to increase the scheduled number of leukaphereses and in this case, the extra leukapheresis was important in contributing to a combined yield of 42.0 Â 10 6 CD34 þ cells/kg. Of the 18 patients who successfully collected 42.0 Â 10 6 CD34 þ cells/kg with the second rHuSCF-based mobilization alone a similar analysis was performed showing no significant difference in the mean number of apheresis procedures between the first and second mobilizations (2.6 vs 3.3;
We compared the number of CD34 þ Â 10 6 cells/kg collected per leukapheresis from the G-CSF-based regimen Table 2 Yield of PBSC with and without chemotherapy as part of the mobilization schedule with that of the rHuSCF-based regimen to gauge the mobilization effect of adding rHuSCF. When compared to the G-CSF-based regimen, the mean daily yield of CD34 þ cells was consistently higher for the rHuSCF-based regimen. These differences in PBSC yield were statistically significant except on day 4. This most likely reflects the small number of patient's undergoing collection on day 4. Furthermore, the mean total yield of CD34 þ cells ( Â 10 6 cells/kg) from the group as a whole was significantly higher with the rHuSCF-based regimen compared to the G-CSF-based regimen. These results are summarized in Table 4 . In contrast to the G-CSF-based regimen, a feature of the rHuSCF-based regimen is that, the PBSC yields are maintained across progressive daily leukaphereses and collection totals decline slowly, allowing a longer collection time (Figure 2 ).
Prognostic factors
Univariate analysis. A PBSC yield of 42.0 Â 10 6 CD34 þ cells/kg was used as the threshold for successful collection as this enabled the patient to proceed to a transplant if required. Data were analysed to ascertain which potential prognostic factors contributed to a PBSC yield of 42.0 Â 10 6 CD34 þ cells/kg. The factors analysed included age, gender, primary disease, duration of disease, stage of disease at diagnosis, performance status prior to collection, bone marrow involvement, lactate dehydrogenase (LDH), albumin, b 2 microglobulin (b2M), base line full blood examination (FBE), duration since last course of chemotherapy before mobilization and the total PBSC yield from the G-CSF-based regimen. Five variables were identified on univariate analysis to be associated with the specified end point, all of which were statistically significant. When analysed by disease, multiple myeloma patients were more likely to successfully mobilize sufficient PBSC for a subsequent transplant than patients in other disease categories. This information is summarized in Table 5 . Figure 1 Outcomes following remobilization. Multivariate analysis/predictive model. Although the total number of PBSC collected from the G-CSF-based regimen is an important predictor, there was no finite number below which a subsequent successful collection cannot be attained. While 21/24 (87%) of patients with a total CD34 þ yield of 40.5 Â 10 6 /kg from the previous G-CSFbased regimen were able to achieve sufficient PBSC for a transplant following remobilization with the rHuSCFbased regimen, a significant portion of patients 8/24 (33%), with a total CD34 þ yield of o0.5 Â 10 6 /kg from the previous G-CSF-based regimen were also able to achieve this goal. As the total PBSC yield from the previous G-CSF-based regimen alone cannot conclusively delineate successful mobilizers with the rHuSCF-based regimen, we propose an algorithm that will allow physicians to accurately predict which patients are most likely to subsequently have a successful collection using rHuSCF. The total number of CD34 þ cells ( Â 10 6 /kg) collected from the initial G-CSF-based regimen and the total number of CD34 þ cells ( Â 10 6 /kg) collected from day 1 of the subsequent rHuSCF-based regimen are independent predictors of the defined end point. These two factors in combination can be used to formulate a model to predict the expected cumulative total of PBSC ( Â 10 6 /kg) expected if physicians were to persist with a total of five leukaphereses in heavily pre-treated patients following remobilization with an rHuSCF-based regimen: where CT* is the cumulative total of PBSC collected from the G-CSF-based regimen plus the rHuSCF-based regimen.
Transplant outcomes
Of the 29 patients, 12 who were successfully remobilized have been transplanted. Prior to engraftment two of these patients died from overwhelming sepsis. Of the remaining patients, the median time to neutrophil recovery of 
Table 5
Prognostic factors on univariate analysis that influence the probability of a successful collection . In this small number of patients there was no significant relationship between time to engraftment and number of PBSC transplanted or number of leukaphereses required to collect these cells. Whilst the engraftment kinetics are slightly slower than those observed with patients mobilized just once at our institution (data not shown), the number of patients analysed are too few to draw firm conclusions on the quality of the PBSC gained from the second rHuSCF-based mobilization.
Discussion
This study demonstrates that rHuSCF, when incorporated into a previously unsuccessful G-CSF-based regimen, can enhance PBSC mobilization in heavily pre-treated patients with a variety of haematological malignancies who have declared themselves as poor mobilizers.
In this study, we clearly demonstrated using a standard 7 l blood volume leukapheresis that patients mobilized a significantly greater daily and total amount of PBSC with the rHuSCF-based regimen as compared to their previous attempt with a G-CSF-based regimen. Our results contrast with those reported by Da Silva et al, 28 who failed to demonstrate an increased mobilization efficacy using an rHuSCF-based regimen in those who had previously failed a G-CSF-based regimen. In contrast to our study, the study by Da Silva et al contained fewer patients and included patients with solid tumours. Leukapheresis was commenced on different days of cytokine therapy in the two centres involved and not all the patients included received cytokine therapy until the completion of leukapheresis. Finally, none of the patients included in the study by Da Silva et al were remobilized with chemotherapy as part of the regimen.
We have demonstrated that 60% of patients who were previously unable to proceed to an autologous transplant were afforded this opportunity following remobilization using an rHuSCF-based regimen. Of these, 38% of the patients were able to collect 42.0 Â 10 6 CD34 þ cells/kg with the rHuSCF-based regimen alone. Our results are consistent and compare favourably with results on remobilization with rHuSCF-based regimens reported by To et al 16 and Azar et al (in abstract form). 29 It should be noted that the patients included in both these previous studies were not a heavily pre-treated cohort.
Patients mobilized with chemotherapy as part of the G-CSF-based and rHuSCF-based regimens collected higher levels of PBSC than those mobilized with cytokine therapy alone. Recent reports suggest that the mobilization of stem cells is initiated by stress-induced activation of the bone marrow environment. 30, 31 Integral to this process is the chemokine stromal cell-derived factor-1 (SDF-1). Numerous investigators have demonstrated increased levels of SDF-1 within the bone marrow environment following the administration of chemotherapy. 32, 33 This transient increase in SDF-1 mediates the release of several downstream proteolytic enzymes that alter the cytokine milieu of the bone marrow environment eventually leading to the proliferation and release of stem cells. The improved mobilization with chemotherapy demonstrated in this study supports this notion, and suggests that chemotherapy should be included as part of the mobilization schedule in patients who are heavily pre-treated and remobilized with an rHuSCF-based regimen.
Patients with multiple myeloma were also more likely than patients in other disease categories to remobilize successfully. The addition of bisphosphonate therapy to G-CSF mobilization has previously been reported to increase the PBSC yield in a murine model. 34 This finding in our cohort of myeloma patients receiving rHuSCF has not been previously demonstrated and may represent an in vivo synergism between rHuSCF, G-CSF and bisphosphonate therapy. The baseline platelet count, albumin and performance status were also variables that were noted to be significantly associated with a cumulative total of PBSC adequate for transplantation. This most likely reflects the relative preservation of the haematopoietic environment, nutritional reserve and physical condition of the patients involved. It is intuitive that these are essential components required by patients to successfully mobilize PBSC.
The previous total of PBSC harvested with a G-CSFbased regimen is the most significant predictor of a successful collection following remobilization with an rHuSCF-based regimen. However, there is no threshold below which a successful collection can no longer be attained. Patients who had collected o0.5 Â 10 6 CD34 þ cells/kg with G-CSF-based treatment were excluded from previous studies assessing successful remobilization with an rHuSCF-based schedule. 16 However, we have demonstrated in this study that 33% of patients in this category achieve sufficient PBSC for autologous transplantation following remobilization with an rHuSCF-based regimen.
The total PBSC yield from the G-CSF-based regimen in combination with the day 1 PBSC harvest following the rHuSCF-based regimen can be used in a predictive model to select patients that are likely to collect sufficient PBSC for autologous transplantation. This model will allow for the early identification of patients likely to succeed in attaining 42.0 Â 10 6 CD34 þ cells/kg and will appropriately exclude patients who are never likely to achieve a successful PBSC collection. In practise this will decrease the number of unsuccessful leukaphereses performed and reduce the risk and expense associated with further unnecessary cytokine therapy.
The main limitation of this study is that there was no active control group. Previous studies have indicated that in general, remobilization with the same schedule yields the same poor result. 35, 36 However, remobilization with dose escalation of G-CSF alone has resulted in more favourable outcomes. 37, 38 A randomized control trial of remobilization, comparing dose escalation of G-CSF alone with an rHuSCF-based regimen needs to be conducted. This will allow the evaluation of the merits of rHuSCF with respect to cost and efficacy in heavily pre-treated patients and also permit the validation of the predictive model proposed in this study. In conclusion, it should be noted that several newer agents such as AMD3100 are being developed and show significant promise. 39 These agents will add to the repertoire of stem cell mobilizers, and may further delineate the algorithm for hard to mobilize patients.
